Physician profile
David A Pearson
NPI 1811136385
$1,721.32
in general payments reported to CMS, 2019-2025
16 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $147 · 2022: $68.07 · 2023: $612 · 2024: $484 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,506.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $583.14 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $408.53 | 2021-2023 | |
| Novo Nordisk INC | $293.71 | 2021-2025 | Wegovy |
| Inari Medical, INC. | $132.26 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Merck Sharp & Dohme LLC | $75.02 | 2021-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
| Lilly USA, LLC | $52.40 | 2022-2023 | Mounjaro |
| Lundbeck LLC | $21.19 | 2024 | Rexulti |
| Althera Pharmaceuticals LLC | $20.62 | 2022 | |
| Astellas Pharma US INC | $18.94 | 2023 | Veozah |
| Boston Scientific Corporation | $17.81 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.52 | 2021 | |
| Glaxosmithkline, LLC. | $17.04 | 2023 | Arexvy |
| Paratek Pharmaceuticals, INC. | $16.89 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.82 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $14.85 | 2024 | Rexulti |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $14.58 | 2023 | Fanapt, Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.